PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August 30 to September 4 in Barcelona, Spain. The new clinical trial data and GHEOR analyses assessing cost effectiveness and real-world use reinforce the alliance’s commitment to the ongoing analysis of Eliquis in both the NVAF and VTE patient populations.
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014 | Pfizer Pharmaceutical News and Media | Pfizer: the world's largest research-based pharmaceutical company
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.